Evidence map›Paper›PMID 41793590›Full record

ArticleScience China. Life sciences2026

Targeting methionine-induced pyroptosis enhances anti-tumor immunity.

Mingzhu Lei, Wenying Zhu, Chao Wang, Fan Zhang, Miaolin Li, Yi Zhang, Jia Qu, Zhiguo Luo, Jintao Li, Zeng-Xia Li and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mingzhu Lei *Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Wenying Zhu *Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Chao WangFudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Fan ZhangFudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Miaolin LiFudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Yi ZhangFudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Jia QuFudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Zhiguo LuoDepartment of Oncology, Shanghai Medical College; Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Jintao LiFudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Zeng-Xia LiPublic technology platform, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Miao YinFudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. miaoyin@fudan.edu.cn.
Qun-Ying LeiFudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; Shanghai Key Laboratory of Medical Epigenetics; National Key Laboratory of Brain Function and Diseases; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. qlei@fudan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyroptosis is an inflammatory form of programmed cell death that plays a critical role in tumor immunity. However, the metabolic signals involved in this process remain undefined. In the present study, we uncover that methionine metabolism plays an important role in the pyroptosis of bone marrow-derived macrophages (BMDMs). The depletion of methionine adenosyltransferase 2A (Mat2a) in macrophages leads to cell death by activating GSDME, resulting in suppression of tumor growth in vivo. Furthermore, pharmacological inhibition of MAT2A induces macrophage pyroptosis by activating Gasdermin E (GSDME) but not Gasdermin D (GSDMD). Moreover, we identify a natural compound 1,2,3,4,6-O-pentagalloylglucose (PGG), not only inhibiting the enzymatic activity of MAT2A but also promoting its proteasome degradation through E3 ligase SMURF1-mediated polyubiquitylation. Consequently, PGG can induce pyroptosis by cleaving GSDME in various tumor cells and suppress tumor cell growth through enhancing anti-tumor immune response. Collectively, our findings reveal that MAT2A is an essential metabolic regulator of pyroptosis, and PGG could potentially boost anti-tumor immunity by targeting MAT2A.

Indexed as

MethionineMethionine AdenosyltransferaseNeoplasmsPyroptosisAnimalsCell Line, TumorGasderminsHumansMacrophagesMiceMice, Inbred C57BLGasderminsMethionineMethionine AdenosyltransferaseGSDMEmacrophageMAT2Apyroptosistumor immunity

Identifiers

PMID41793590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.